Israel-based Tarsier Pharma files for an expanded IPO aiming to raise nearly $50M in gross proceeds on US markets.
Tarsier Pharma, a late-stage biopharmaceutical company specializing in eye disease treatments, has upsized its initial public offering in the US, targeting nearly $50M in gross proceeds. The Israel-based firm submitted a regulatory filing this week to expand its IPO plans.
The company previously indicated smaller fundraising ambitions but revised its target upward in the latest filing. Tarsier focuses on developing therapies for ocular conditions, though specific drug candidates or clinical trial stages were not detailed in the release.
No immediate market reaction was reported following the filing announcement.